Amarin (AMRN -7.8%) comes under pressure after the FDA's update to its Orange Book gives it's fish oil pill Vascepa "no unexpired exclusivity," though no NCE decision was made. [View news story]
Those who only look at the downside are confirmed bears, Those who look at all sides make good decisions. AMRN good side outweighs downside considerably. FDA does not need to buy off on anything that has such tremendous potential. Time will tell.
Amarin (AMRN -7.8%) comes under pressure after the FDA's update to its Orange Book gives it's fish oil pill Vascepa "no unexpired exclusivity," though no NCE decision was made. [View news story]